Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effekten av et smarttelefonassistert hybrid hjerterehabiliteringsprogram hos pasienter med hjertesvikt. (SHCR-HF)

15. november 2026 oppdatert av: National Taiwan University Hospital

The aim of this randomized controlled trial is to compare the impact of a case manager-led smartphone-assisted hybrid cardiac rehabilitation program with usual care in patients with HF. Participants will undergo a 12-week program led by a case manager and assisted by a smartphone. The study aims to answer two main questions:

  1. Is the novel cardiac rehabilitation model feasible for patients with HF?
  2. Does the intervention group show a significant improvement in exercise capacity and adherence compared to the usual care group?

Studieoversikt

Status

Rekruttering

Forhold

Studietype

Intervensjonell

Registrering (Antatt)

150

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Hung-Jui Chuang, MD
  • Telefonnummer: 67034 00886-2-23123456
  • E-post: rexintwo@gmail.com

Studiesteder

      • Taipei, Taiwan
        • Rekruttering
        • Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 80 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Patients with heart failure between the ages of 18 and 80 years old.
  • NYHA (New York Heart Association) functional classification of 1 to 3.
  • Patients must be in a stable condition and under outpatient follow-up.

Exclusion Criteria:

  • Patients who have contraindications for exercise according to the American College of Sports Medicine's Guidelines for Exercise Testing and Prescription.
  • Patients who are unable to complete cardiopulmonary exercise testing.
  • Patients who are unable to follow verbal instructions.
  • Patients who are unable to walk independently or pedal a stationary bicycle.
  • Patients who are unable to use communication app on a smartphone.
  • Patients who already engage in physical activity exceeding the recommended moderate intensity of 150 minutes per week or are currently participating in cardiac rehabilitation.
  • Patients who do not provide consent to participate in the trial.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: smartphone-assisted hybrid cardiac rehabilitation (SHCR)

Participants receive a 12-wk case manager-led smartphone-assisted hybrid cardiac rehabilitation with follow-up at 12 week and 6 months.

The 12-week case manager-led SHCR program includes:

  • Customized exercise prescriptions following ACSM's heart failure guidelines.
  • A hybrid program combining in-person sessions, home self-exercise, and videoconferencing for exercise coaching(optional), supported by a smartphone app.
  • Case managers instruct patients on a communication app for weekly follow-ups, health education messages, exercise reminders, and progress tracking, including metrics like blood pressure, heart rate, weight, and symptoms.
Ingen inngripen: Usual care

Participants receive usual care including general education and exercise suggestion.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change of peak oxygen uptake
Tidsramme: at baseline, 12 weeks(post-intervention), and 6 months.

Peak oxygen uptake will be assessed using cardiopulmonary exercise test before intervention, at 12 weeks (post-intervention), and at 6 months.

at baseline, 12 weeks(post-intervention), and 6 months.
Change of 6 minute walking test
Tidsramme: at baseline, 12 weeks(post-intervention), and 6 months.

6 minute walking test will be performed before intervention, at 12 weeks (post-intervention), and at 6 months.

at baseline, 12 weeks(post-intervention), and 6 months.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Adherence to prescribed exercise
Tidsramme: 12 weeks(post-intervention)

We will evaluate the percentage of completed prescribed exercises at 12 weeks.

12 weeks(post-intervention)
Evaluation of Quality of life
Tidsramme: at baseline, 12 weeks(post-intervention), and 6 months.

The investigators will assess the change in 36-Item Short Form Survey(SF-36).

at baseline, 12 weeks(post-intervention), and 6 months.
Depression
Tidsramme: at baseline, 12 weeks(post-intervention), and 6 months.

The investigators will assess the change in Patient Health Questionnaire (PHQ-9). The PHQ-9 score ranges from 0-27. Higher scores indicate worsen symptoms.

at baseline, 12 weeks(post-intervention), and 6 months.
Anxiety
Tidsramme: at baseline, 12 weeks(post-intervention), and 6 months.

The investigators will assess the change in Generalized Anxiety Disorder scale (GAD-7). The GAD-7 score ranges 0-21. Higher scores indicate worsen symptoms.

at baseline, 12 weeks(post-intervention), and 6 months.
Evaluation of physical activity
Tidsramme: at baseline, 12 weeks(post-intervention), and 6 months.

The investigators will assess the change in physical activity using International Physical Activity Questionnaire(IPAQ) Taiwan version.

at baseline, 12 weeks(post-intervention), and 6 months.
Evaluation of grip strength
Tidsramme: at baseline, 12 weeks(post-intervention), and 6 months.

The grip strength will be measured using a grip goniometer with the participants seated and the elbow flexed at 90 degrees.

at baseline, 12 weeks(post-intervention), and 6 months.
Evaluation of frailty
Tidsramme: at baseline, 12 weeks(post-intervention), and 6 months.

The investigators will evaluate the change in the Clinical Frailty Scale, which ranges from 1 to 9. Higher scores represent greater illness.

at baseline, 12 weeks(post-intervention), and 6 months.
Blood test: Total cholesterol
Tidsramme: at baseline, 12 weeks(post-intervention), and 6 months.

The Total cholesterol will be tested in the laboratory.

at baseline, 12 weeks(post-intervention), and 6 months.
Blood test: LDL
Tidsramme: at baseline, 12 weeks(post-intervention), and 6 months.

The LDL will be tested in the laboratory.

at baseline, 12 weeks(post-intervention), and 6 months.
Blood test: HDL
Tidsramme: at baseline, 12 weeks(post-intervention), and 6 months.

The HDL will be tested in the laboratory.

at baseline, 12 weeks(post-intervention), and 6 months.
Blood test: Triglyceride
Tidsramme: at baseline, 12 weeks(post-intervention), and 6 months.

The Triglyceride will be tested in the laboratory.

at baseline, 12 weeks(post-intervention), and 6 months.
Blood test: NT-proBNP
Tidsramme: at baseline, 12 weeks(post-intervention), and 6 months.

The NT-proBNP will be tested in the laboratory.

at baseline, 12 weeks(post-intervention), and 6 months.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Hung-Jui Chuang, MD, Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

26. januar 2024

Primær fullføring (Antatt)

1. desember 2028

Studiet fullført (Antatt)

1. desember 2028

Datoer for studieregistrering

Først innsendt

1. mai 2023

Først innsendt som oppfylte QC-kriteriene

15. mai 2023

Først lagt ut (Faktiske)

24. mai 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • 202302009RINC

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere